Correction

“…mAbs…”
Get full text

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro by Omar S. Qureshi, Emma J. Sutton, Rosemary F. Bithell, Shauna M. West, Rona M. Cutler, Gillian McCluskey, Graham Craggs, Asher Maroof, Nicholas M. Barnes, David P. Humphreys, Stephen Rapecki, Bryan J. Smith, Anthony Shock

“…mAbs…”
Get full text

Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study by Dmitry Shchelokov, Oleg Demin Jr

“…mAbs…”
Get full text

Alternative splicing for tuneable expression of protein subunits at desired ratios by Christel Aebischer-Gumy, Pierre Moretti, Timothee Brunstein Laplace, Jana Frank, Ysaline Grand, Farid Mosbaoui, Emilie Hily, Anna Galea, Megane Peltret, Carole Estoppey, Daniel Ayoub, Roberto Giovannini, Martin Bertschinger

“…mAbs…”
Get full text

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors by Kerry A. Whalen, Kavya Rakhra, Naveen K. Mehta, Alexander Steinle, Jennifer S. Michaelson, Patrick A. Baeuerle

“…mAbs…”
Get full text

Multivalent design of the monoclonal SynO2 antibody improves binding strength to soluble α-Synuclein aggregates by Inga Petersen, Muhammad Ilyas Ali, Alex Petrovic, Anders Jimmy Ytterberg, Karin Staxäng, Monika Hodik, Fadi Rofo, Sina Bondza, Greta Hultqvist

“…mAbs…”
Get full text

Extending the capabilities of intact-mass analyses to monoclonal immunoglobulins of the E-isotype (IgE) by Wenhua Yang, Daniil G. Ivanov, Igor A. Kaltashov

“…mAbs…”
Get full text

The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity by Michael J. Knight, Léontine Floret, Nisha Patel, John O’Hara, Elizabeth Rodriguez

“…mAbs…”
Get full text